Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P13645

UPID:
K1C10_HUMAN

ALTERNATIVE NAMES:
Cytokeratin-10; Keratin-10

ALTERNATIVE UPACC:
P13645; Q14664; Q8N175

BACKGROUND:
Keratin-10, identified by the alternative names Cytokeratin-10 and Keratin-10, is pivotal in skin health, contributing to the epidermal barrier's establishment and the maintenance of epithelial cell structure. Its role extends to mediating microbial adherence, indicating a broader significance in immune defense mechanisms.

THERAPEUTIC SIGNIFICANCE:
The association of Keratin-10 with skin diseases such as Epidermolytic hyperkeratosis and Ichthyosis, annular epidermolytic, highlights its therapeutic relevance. Targeting Keratin-10's pathways could lead to innovative treatments for these skin conditions, offering hope for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.